FDA Warning Letter

Regulatory Event

On July 13, 2026, FDA issued Warning Letter 320-26-102 to Almon Healthcare Private Limited, an active pharmaceutical ingredient manufacturer at Plot No 4, Sankalp Industrial Estate, Bavala, Ahmedabad, Gujarat, India, following an inspection conducted February 9 to 13, 2026. The primary finding is not a testing gap or a documentation lapse. FDA’s investigators documented that Almon’s quality unit knowingly accepted raw material lots deliberately mislabeled by its supplier, admitted this was a deliberate practice ongoing since 2024 to circumvent the firm’s lack of a required license, and used the mislabeled, untested material to manufacture multiple API batches shipped to the United States.

The mechanism FDA describes is a full-scale bypass of 21 CFR 211.84(d)(2), which requires that each lot of a component be tested for conformity to appropriate specifications for identity, strength, quality, and purity before use in production. Almon’s quality unit performed no identity testing on the incoming material at all. Instead, it relied on the supplier’s certificate of analysis without conducting the supplier qualification that the firm’s own standard operating procedures required. That is a materially different failure than a missed test — it is a quality unit that knew the labeled identity of an incoming material was false, accepted it anyway, and manufactured finished API against a specification it could not verify. FDA’s letter states plainly that the mislabeled substance is acutely toxic to humans and has caused fatal poisoning incidents worldwide, meaning the exposure risk extended beyond patients to Almon’s own production personnel, who handled a hazardous material without knowing its true identity or the precautions its handling required.

Almon’s response, submitted after the March 6, 2026 Form FDA 483, tried to close the finding with a retrospective reevaluation of residual solvent chromatographic data, asserting the observed peaks were attributable to the mislabeled material’s true identity rather than contamination. FDA rejected this as unsubstantiated because the response supplied no chromatograms or identity test results to support the conclusion. More significantly, FDA noted the absence of any risk assessment covering batches already distributed to the United States and the absence of any corrective action addressing the systemic failure that allowed a quality unit to knowingly recode mislabeled material in the first place. A retrospective data reinterpretation is not a substitute for the identity testing that should have occurred before release; it does not answer what happened to product already in US commerce.

What the Record Documents

This pattern is not new to FDA’s international API enforcement history. FDA placed the Ranbaxy Laboratories Dewas facility in India under Import Alert 66-40 in January 2013 after finding that the site had manipulated stability data and submitted abbreviated new drug application packages that did not reflect actual testing outcomes — an enforcement action that came five years after the Paonta Sahib import alert and established that FDA’s posture toward international API sites is data-integrity-outcome-dependent, not inspection-cycle-dependent. Sun Pharmaceutical Industries’ Toansa facility received a Warning Letter in 2014 citing 21 CFR 211.84(d)(2) for inadequate identity and purity testing of incoming raw materials, requiring a full 36-month audit of impurity data for API lots already released to US commercial markets and 22 months of heightened FDA surveillance before shipments resumed. Almon’s finding sits squarely inside this same enforcement lineage: a quality unit failure at the raw material gate, discovered years after the underlying practice began, with US-distributed product already in commerce by the time FDA intervened.

The second observation compounds the first. Almon had not validated or adequately verified the analytical methods used to support retest dates for API shipped to the United States, including methods that should be stability-indicating. A method transferred from its contract testing laboratory was implemented in a way that could not detect multiple unknown impurities that the contract laboratory’s validated method identified — Almon attributed the discrepancy to an incorrectly set processing threshold rather than a fundamental equivalence gap between the two methods. Under the International Council for Harmonisation (ICH) Q3A(R2) guideline, for a drug substance with a maximum daily dose at or below 2 grams, an impurity becomes reportable at 0.05%, requires structural identification at 0.10%, and requires qualification data at 0.15%. An analytical method that misses impurities the validated comparator method detects is not a calibration nuance; it means every retest date and every disposition decision made using that method was made without adequate scientific evidence that the API met its established specification. FDA correctly identified that Almon proposed no interim controls for production continuing under unvalidated methods while a retrospective review of already-tested batches was pending.

Technical and Quality Context

The third observation is a cleaning validation failure on non-dedicated equipment used to manufacture multiple different APIs. FDA’s investigator documented particles on product-contact surfaces and liquid draining from equipment that had been documented as “empty and cleaned,” and Almon confirmed it had never performed formal cleaning validation or established a maximum allowable carryover limit as its own procedure required. Under 21 CFR 211.67 and the cleaning validation expectations in ICH Q7 Section 12, shared manufacturing equipment requires a scientifically justified carryover limit based on solubility, difficulty of cleaning, and toxicity of the residue — not a “gross cleaning” practice between campaigns with no supporting data. Almon’s claim that a shared transfer pipe was in fact dedicated contradicted what its own personnel told the investigator during the inspection, and the firm confirmed it does not use cleaning logs at all.

FDA placed all drugs and drug products offered for import into the United States from Almon on Import Alert 66-40 on June 9, 2026, more than a month before this Warning Letter issued — a sequencing that reflects how quickly FDA now acts on data-integrity-adjacent findings at international API sites rather than waiting for the formal letter to restrict entry. FDA has recommended Almon engage a qualified Current Good Manufacturing Practice (CGMP) consultant to perform a comprehensive six-system audit of the firm’s entire operation, evaluating the completion and efficacy of corrective actions before Almon pursues resolution of its compliance status.

Decision Relevance

For companies sourcing API from international sites, particularly those supplying compounding pharmacies or generic manufacturers, the Almon letter carries three specific lessons. First, a certificate of analysis is not a substitute for identity testing under 21 CFR 211.84(d)(2), regardless of how established the supplier relationship appears; supplier qualification programs must include periodic verification testing, not passive reliance on paper documentation. Second, when a method transfer from a contract testing laboratory shows any discrepancy in impurity detection against the source method, the receiving site must treat that as a method equivalence failure requiring investigation, not a threshold adjustment to reconcile the numbers after the fact. Third, cleaning validation on shared equipment is not optional documentation; it requires a defensible, science-based carryover limit before the equipment is used across multiple APIs, and physical observations that contradict a firm’s own procedural claims will be treated by FDA as evidence of a systemic quality failure, not an isolated housekeeping issue.

Companies managing international API supply chains, Drug Master File (DMF)-referenced raw materials, or contract laboratory method transfers should assess whether their supplier qualification programs include independent verification testing beyond certificate-of-analysis reliance. XGene’s Chemistry, Manufacturing, and Controls (CMC) regulatory strategy and Warning Letter remediation practice works with API manufacturers and their US-market customers to rebuild supplier qualification programs, validate analytical method transfers against ICH Q2(R2), and design the cleaning validation and corrective and preventive action (CAPA) framework FDA expects before a site can be released from Import Alert restriction. If your organization is assessing exposure from an international API supplier or preparing for FDA reinspection, connect with Khaled Aamer on LinkedIn or at xgeneconsulting.com.